Notice of Award

Award# 1 U01DP006613-01-00

FAIN# U01DP006613

Federal Award Date: 03/25/2021

Recipient Information

1. Recipient Name

Missouri Department of Health 920 Wildwood Dr Community and Public Health Jefferson City, MO 65109-5796 [NO DATA]

2. Congressional District of Recipient

- 3. Payment System Identifier (ID)
- 4. Employer Identification Number (EIN)
- 5. Data Universal Numbering System (DUNS)
- 6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Dr. Rebecca Lander Senior Epidemiology Specialist rebecca.lander@health.mo.gov 573-522-4839

8. Authorized Official

Mrs. Marcia Mahaney
Director, Division of Admnistration
marcia.mahaney@health.mo.gov
573-751-6014

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Ms. Ester Edward Grants Management Specialist/Officer ece9@cdc.gov (770) 488-2852

10.Program Official Contact Information

Sue Shaw ZGX7@cdc.gov 770-488-6142

Federal Award Information

11. Award Number

1 U01DP006613-01-00

12. Unique Federal Award Identification Number (FAIN)

U01DP006613

13. Statutory Authority

Section 317K of the Public Health Service Act, [42 U.S.C. 247b-12], as amended

14. Federal Award Project Title

COMPONENT A - MISSOURI PREGNANCY RISK ASSESSMENT MONITORING SYSTEM

15. Assistance Listing Number

93.946

16. Assistance Listing Program Title

Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs

17. Award Action Type

New

18. Is the Award R&D?

Yes

Summary Federal Award Financial Information

10	Budget Period Start Date	05/01/2021	- End Date	04/20/2022

0. Total Amount of Federal Funds Obligated by this Action \$160,020.0		
20a. Direct Cost Amount	\$135,383.00	
20b. Indirect Cost Amount	\$24,637.00	
21. Authorized Carryover	\$0.00	
22. Offset	\$0.00	
23. Total Amount of Federal Funds Obligated this budget period	\$0.00	

24. Total Approved Cost Sharing or Matching, where applicable \$0.00

25. Total Federal and Non-Federal Approved this Budget Period \$160,020.00

26. Project Period Start Date 05/01/2021 - End Date 04/30/2026

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period

\$160,020.00


28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Ferrinnia Augustus High Grants Management Specialist/Officer

30. Remarks



Notice of Award

Award# 1 U01DP006613-01-00

FAIN# U01DP006613

Federal Award Date: 03/25/2021

Recipient Information

Recipient Name

Missouri Department of Health 920 Wildwood Dr

Community and Public Health Jefferson City, MO 65109-5796

[NO DATA]

Congressional District of Recipient

03

Payment Account Number and Type

Employer Identification Number (EIN) Data

Universal Numbering System (DUNS) 878092600

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement


32. Type of Award

Research

2	
33. Approved Budget (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Ag	ency Only
II. Total project costs including grant funds and all o	
a. Salaries and Wages	\$81,436.00
b. Fringe Benefits	\$41,136.00
c. TotalPersonnelCosts	\$122,572.00
d. Equipment	\$0.00
e. Supplies	\$8,000.00
f. Travel	\$0.00
g. Construction	\$0.00
h. Other	\$4,811.00
i. Contractual	\$0.00
j. TOTAL DIRECT COSTS	\$135,383.00
k. INDIRECT COSTS	\$24,637.00
1. TOTAL APPROVED BUDGET	\$160,020.00
m. Federal Share	\$160,020.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-939ZRDR	21U01DP006613	DP	41.41	\$160,020.00	75-21-0948



Award# 1 U01DP006613-01-00

FAIN# U01DP006613

Federal Award Date: 03/25/2021

35. Terms And Conditions

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
05/01/2021	04/30/2022	Annual	07/29/2022

AWARD ATTACHMENTS

Missouri Department of Health

1 U01DP006613-01-00

1. Terms and Conditions

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Research awards at

https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number RFA-DP-21-001, entitled Pregnancy Risk Assessment Monitoring System (PRAMS), and application dated August 7, 2020, as may be amended, which are hereby made a part of this Research award hereinafter referred to as the Notice of Award (NOA).

Note: Due to grants management administration system parameters, the budget category names on Page 1 of this NOA may be altered from the budget categories submitted with the SF-424 Research and Related Budget application.

Approved Funding: Funding in the amount of \$160,020 is approved for the Year 01 budget period, which is May 1, 2021 through April 30, 2022. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
Component A	\$ 160,020

Recipients are to review the **Payment Management System (PMS) Subaccount** section in this document to determine the appropriate subaccount document number for the referenced Component. Program specific authorizing legislation, budgetary appropriations, or similar authority may require the creation of more than one subaccount document number per award.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: It is anticipated that CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

- Maintain CDC Institutional Review Board approvals as required when engaged in research involving human subjects.
- Obtain Office of Management and Budget (OMB) approval in accordance with the Paperwork Reduction Act (PRA), as required.
- Provide model procedures and assist with development of jurisdiction-specific

- written procedures. Conduct periodic review of written procedures and provide recommendations for improvement if needed.
- Provide CDC-provided software system for use in data collection procedures and monitoring of PRAMS operational data.
- Provide training, operations management and ongoing technical support for CDC supported software.
- Assist with the specification of variable descriptions and format layouts of all data files.
- · Assist with the development of computer programs for sampling and analysis.
- Provide statistical guidance on development, implementation, and modification of sampling plan.
- · Provide technical assistance to resolve problems in data collection procedures.
- Conduct regular operational evaluations and provide recommendations for improvements if needed.
- · Provide technical assistance for data editing.
- Provide technical assistance on implementation of survey supplements to address emerging issues that may arise during the project.
- Assist with implementation of a new version of the questionnaire (Phase 9) with potential adaptions to the existing PRAMS methodology (e.g. online data collection) in conjunction with awardees and stakeholders in maternal and infant health.
- Provide awardees with epidemiologic technical assistance including identifying relevant data sources, developing descriptive analyses and preparing reports on a range of topics.
- Conduct the statistical weighting and create annual data sets for awardees.
 Processing of data for weighted data sets by CDC is subject to awardees' adherence to protocol and meeting a minimum response rate target.
- Assist awardee staff in obtaining training in software to analyze PRAMS data.
- Facilitate the dissemination of weighted analytic datasets to researchers per data sharing agreement.
- Facilitate dissemination and translation of findings for use in development and evaluation of MCH programs.
- Organize on-going opportunities for exchange of information on challenges and best practices in establishing surveillance or other enhanced activities.
- Participate with awardees in workshops, trainings, meetings, and coordinating committees to exchange information among awardees.
- Coordinate and participate in PRAMS National Awardee Meetings.
- Participate in the voluntary PRAMS Coordinating Committee comprised of CDC Project Scientists and awardees to promote exchange of information and best practices for program development and evaluation.
- Assist awardee with complying with the CDC PRAMS Standard Data Management Plan for AR25 https://www.cdc.gov/grants/additionalreguirements/ar-25.html.

Summary Statement Response: Any strengths and weaknesses of the proposal performance progress will be communicated via email directly from the CDC Scientific Program Officer/Program Official (SPO/PO) noted in the Staff Contacts section of this NoA. A response must be submitted via email to the SPO/PO by the due date of, June 1, 2021. Failure to respond will cause delay in programmatic progress and may adversely affect the future funding of this project.

Expanded Authority: The recipient is permitted expanded authorities in the administration of the award.

The expanded authorities selected below apply to this NoA.

- ☑ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report submitted in eRA Commons. If the GMO determines that some or all the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.
- ⊠ Extension of final budget period of a period of performance without additional funds up to 12 months with no change in the scope of work to ensure adequate completion of the originally approved project or program. The recipient must notify the awarding office, in writing, of the extension 10 days before the expiration date of the period of performance. Upon notification, the awarding office will revise the period of performance ending date and provide an acknowledgement to the recipient.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

<u>Addition alternative</u>: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Human Subjects Restriction(s): Research involving human subjects cannot begin until a copy of the IRB approval letter for each of the institution sites is submitted and a revised NoA releasing the restriction is issued, in writing, by the Grants Management Officer.

- A funding restriction in the amount of \$16,002 has been placed on this award pending IRB approvals.
- The restriction applies to the following budget items or budget categories: Salaries & Wages and Fringe Benefits.

Recipients are advised that documentation for key personnel and other significant contributors involved in the design or conduct of research, that demonstrates completion of an education program in the protection of human subjects, may be required to be submitted concurrently. The recipient should contact the Scientific Program Official noted in the Staff Contacts section of this NoA for more information on Human Subjects Restriction release.

Certificate of Confidentiality: Institutions and investigators are responsible for determining whether research they conduct is subject to Section 301(d) of the Public Health Service (PHS) Act. Section 301(d), as amended by Section 2012 of the 21st Century Cures Act, P.L. 114-255 (42 U.S.C. 241(d)), states that the Secretary shall issue Certificates of Confidentiality (Certificates) to persons engaged in biomedical, behavioral, clinical, or other research activities in which identifiable, sensitive information is collected. In furtherance of this provision, CDC

supported research commenced or ongoing after December 13, 2016 in which identifiable, sensitive information is collected, as defined by Section 301(d), is deemed issued a Certificate and therefore required to protect the privacy of individuals who are subjects of such research. Certificates issued in this manner will not be issued as a separate document, but are issued by application of this term and condition to this award. See Additional Requirement 36 to ensure compliance with this term and condition. The link to the full text is at: https://www.cdc.gov/grants/additionalrequirements/ar-36.html

Indirect Costs:

Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 17, 2020, which calculates indirect costs as follows, a Provisional is approved at a rate of 20.10% of the base, which includes Direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2021 to June 30, 2023.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Ester Edward, MBA, MPH, CGMS
Grants Management Specialist/Officer
Centers for Disease Control and Prevention
Branch 2
2939 Flowers Road
Atlanta, GA 30341
Eav: 404-471-5415 (Include "Mandatory Grants")

Fax: 404-471-5415 (Include "Mandatory Grant Disclosures" in subject line)
Email: ece9@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the first page of the NOA must be known in order to draw down funds.

CDC STAFF CONTACTS

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards. Many of the functions described in the GMO section are performed by the GMS, on behalf of the GMO.

GMS Contact:

Ester Edward, MBA, MPH CGMS
Grants Management Specialist/Officer
Centers for Disease Control and Prevention
Branch 2

Telephone: 770-488-2852 Fax: 404-471-8415 Email: ece9@cdc.gov

Scientific Program Official/Project Officer: The SPO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

Leslie Lipscomb Harrison, M.P.H.
PRAMS Team Leader, Division of Reproductive Health
Centers for Disease Control and Prevention
4770 Buford Hwy. NE/ MS S107-2/ Atlanta, GA 30341
770-488-6335 (ph) / 770-488-6291 (fax)

Email: LHarrison@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to

obligate federal funds and is responsible for signing the NOA, including revisions to the NOA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Ferrinnia (Toni) Augustus-High, MSA, CGMS Grants Management Officer Centers for Disease Control and Prevention Branch 2

Telephone: 770-488-2906

Fax: 404-471-8415 Email: wef9@cdc.gov